|Dr. Michelle Miller BSc., GCertAppFin, Ph.D., MSc.||CEO, MD & Exec. Director||360k||N/A||N/A|
|Mr. Peter James Nightingale C.A., B.Econ, CA||Company Sec.||84k||N/A||1957|
|Dr. Stephen L. Becker M.D.||Chief Medical Officer||N/A||N/A||N/A|
Biotron Limited, a biotechnology company, engages in the developing and commercializing novel small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, including dengue, zika, influenza, ebola, and SARs. Biotron Limited was incorporated in 1999 and is based in North Ryde, Australia.
Biotron Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.